MedPath

IRBESARTAN

These highlights do not include all the information needed to use IRBESARTAN TABLETS safely and effectively. See full prescribing information for IRBESARTAN TABLETS. IRBESARTAN tablets, for oral use Initial U.S. Approval: 1997

Approved
Approval ID

a3a3c7d3-fd55-45b6-9f5c-a9de0b2d8648

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

Oct 2, 2019

Manufacturers
FDA

A-S Medication Solutions

DUNS: 830016429

Products 1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

IRBESARTAN

Product Details

FDA regulatory identification and product classification information

FDA Identifiers
NDC Product Code50090-4519
Application NumberANDA206194
Product Classification
M
Marketing Category
C73584
G
Generic Name
IRBESARTAN
Product Specifications
Route of AdministrationORAL
Effective DateAugust 6, 2019
FDA Product Classification

INGREDIENTS (9)

SILICON DIOXIDEInactive
Code: ETJ7Z6XBU4
Classification: IACT
CROSCARMELLOSE SODIUMInactive
Code: M28OL1HH48
Classification: IACT
POVIDONE K29/32Inactive
Code: 390RMW2PEQ
Classification: IACT
LACTOSE MONOHYDRATEInactive
Code: EWQ57Q8I5X
Classification: IACT
MAGNESIUM STEARATEInactive
Code: 70097M6I30
Classification: IACT
HYPROMELLOSE 2910 (15 MPA.S)Inactive
Code: 36SFW2JZ0W
Classification: IACT
TITANIUM DIOXIDEInactive
Code: 15FIX9V2JP
Classification: IACT
POLYETHYLENE GLYCOL 300Inactive
Code: 5655G9Y8AQ
Classification: IACT
IRBESARTANActive
Quantity: 300 mg in 1 1
Code: J0E2756Z7N
Classification: ACTIB

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

IRBESARTAN - FDA Drug Approval Details